^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma

Published date:
09/14/2020
Excerpt:
In this phase 1 study, adults with relapsed/refractory (RR) acute myeloid leukemia (AML) or diffuse large B-cell lymphoma (DLBCL)...In 63% of patients with RR AML...molecular aberrations were observed, with IDH1/2 and RAS being the most frequently mutated genes....Antitumor activity was observed in patients with AML treated with eftoza-VEN...